J. BanksJ. PooleN. AhrensA. SeltsamA. SalamaK. Hue-RoyeJ. R. StorryP. PalacajornsukB. W. MaD. M. LublinMarion E. ReidNational Blood ServiceCharité – Universitätsmedizin BerlinNew York Blood CenterMahidol UniversityWashington University School of Medicine in St. LouisHanover Medical CollegeLunds Universitet2018-07-242018-07-242004-08-01Transfusion Medicine. Vol.14, No.4 (2004), 313-318095875782-s2.0-4043168377https://repository.li.mahidol.ac.th/handle/20.500.14594/21364The Cromer blood group system consists of eight high incidence and three low incidence antigens carried on decay-accelerating factor (DAF). This report describes the identification and characterization of a new Cromer high incidence antigen, named SERF. Sequence analyses of DNA from a Thai female whose serum contained the alloantibody to a high incidence antigen in the Cromer blood group system (anti-SERF) and from her two children were performed. Reverse transcriptase-polymerase chain reaction (RT-PCR) and sequence analysis on cDNA from the proband and PCR-restriction fragment length polymorphism analysis on DNA from Thais were also performed. To map the epitope, DAF deletion mutants were tested by immunoblotting with anti-SERF. Sequence analysis revealed a substitution of 647C>T in exon 5 DAF in the proband. The proband's two children and two of 100 Thais were heterozygotes 647C/T. Analysis using DAF deletion mutants revealed the antigenic determinant to be within short consensus repeat 3 (SCR3), which is encoded by exon 5. This study describes a novel high incidence antigen (SERF) in the Cromer blood group system characterized by the amino acid proline at position 182 in SCR3 of DAF. The SERF-negative proband has a substitution mutation that predicts for leucine at this position. SERF has been provisionally assigned the International Society of Blood Transfusion number 021-012(CROM 12).Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1111/j.0958-7578.2004.00519.x